Lundbeck's Vyepti Sales Pick Up Against Pandemic Headwinds
Narrows Financial Guidance For 2020
Lundbeck also makes progress in the third quarter with its early clinical-stage neuroscience candidates and indication extension studies for its psychiatry products, while confirming and narrowing revenues and earnings forecasts for the year.
You may also be interested in...
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.